Agents reducing cytokine levels

DrugDrug NameDrug Indication
DB00051AdalimumabThe following are conditions for which adalimumab has been indicated [F2118], [FDA label], [L4805], [A40001], [A40002], [L4806]. Rheumatoid Arthritis (Moderate to Severe) Juvenile Idiopathic Arthritis (Moderately to Severely Active) Psoriatic Arthritis (Active) Ankylosing Spondylitis (Active) Crohn’s Disease (Moderately to Severely Active) Ulcerative Colitis (Moderately to Severely Active) Plaque Psoriasis (Moderate to Severe Chronic) Non-infectious Intermediate, Posterior and Panuveitis Hidradenitis Suppurativa (Moderate to Severe) Pyoderma Gangrenosum (off-label)
DB14724EmapalumabEmapalumab is indicated for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.[L4840] The HLH condition is a hyperinflammatory status characterized by the overwhelming activation of normal T lymphocytes and macrophages which can lead to disturbances in the hematology profile and even death. As part of the condition profile, there have been reports proving a massive overexpression of interferon-gamma which is thought to drive the immune hyperactivation leading to organ failure.[A38676] This condition is usually developed and present the symptomatic profile within the first months or years of life. These symptoms consist of fever, enlarged liver or spleen and a lower number of blood cells.[L4840]
DB00005EtanerceptEtanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis.
DB06674GolimumabUsed in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
DB08904Certolizumab pegolCertolizumab pegol has been approved for several different conditions listed below: - Symptomatic management of Chron's disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy. - Treatment of adult patients with moderate to severely active rheumatoid arthritis. - Treatment of adult patients with active psoriatic arthritis. - Treatment of adult patients with active ankylosing spondylitis. - Treatment of adult patients with moderate-to-severe plaque psoriasis that are candidates for systemic therapy or phototherapy.[FDA label] - Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation.[L5819] In Canada, certolizumab pegol is additionally approved in combination with [methotrexate] for the symptomatic treatment, including major clinical response, and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritis.[L5825] Inflammation is a biological response against a potential threat. This response can be normal but in certain conditions, the immune system can attack the body's normal cells or tissues which causes an abnormal inflammation.[L5840] TNF-alpha has been identified as a key regulator of the inflammatory response. The signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death, survival, differentiation, proliferation and migration.[A176660]
DB00065Infliximab* Indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric (≥ 6 years of age) patients with moderately to severely active **Crohn’s disease** who have had an inadequate response to conventional therapy * Indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing **Crohn’s disease**. * Indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric (≥ 6 years of age) patients with moderately to severely active **ulcerative colitis** who have had an inadequate response to conventional therapy. * Indicated for, in combination with methotrexate, reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active **rheumatoid arthritis**. * Indicated for reducing signs and symptoms in patients with active **ankylosing spondylitis**. * Indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with **psoriatic arthritis**. * Indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) **plaque psoriasis** who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.
DB04956AfelimomabInvestigated for use/treatment in sepsis and septicemia.
DB06168CanakinumabUsed in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA).
DB00026AnakinraFor the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
DB06273TocilizumabIndicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
DB06372RilonaceptRilonacept is currently used in the treatment of cryopyrin-associated periodic syndrome. In May 2012, an advisory panel for the FDA voted 11-0 against the use of Rilonacept for the treatment of gout.
DB09029SecukinumabFor the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy.
DB09036SiltuximabSiltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive.
DB01281AbataceptFor the management of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients. It is indicated both as a monotherapy and for use in combination with a continued regimen of DMARDs (not including TNF antagonists). Also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children.
DB05676ApremilastApremilast is indicated for the treating of active psoriatic arthritis in adults, for the treating of active moderate to severe psoriatic arthritis in patients who are eligible for phototherapy and systemic treatment. In addition, apremilast is now indicated for the treatment of oral ulcers associated with Behcet's disease in adults.[L7501]
DrugDrug NameTargetType
DB00051AdalimumabTumor necrosis factortarget
DB14724EmapalumabInterferon gammatarget
DB00005EtanerceptTumor necrosis factortarget
DB00005EtanerceptLymphotoxin-alphatarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00005EtanerceptComplement C1r subcomponenttarget
DB00005EtanerceptComplement C1q subcomponent subunit Atarget
DB00005EtanerceptComplement C1q subcomponent subunit Btarget
DB00005EtanerceptComplement C1q subcomponent subunit Ctarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00005EtanerceptComplement C1s subcomponenttarget
DB00005EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00005EtanerceptTumor necrosis factor receptor superfamily member 1Btarget
DB06674GolimumabTumor necrosis factortarget
DB08904Certolizumab pegolTumor necrosis factortarget
DB08904Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
DB00065InfliximabTumor necrosis factortarget
DB04956AfelimomabTumor necrosis factortarget
DB06168CanakinumabInterleukin-1 betatarget
DB00026AnakinraInterleukin-1 receptor type 1target
DB06273TocilizumabInterleukin-6 receptor subunit alphatarget
DB06273TocilizumabCytochrome P450 3A4enzyme
DB06372RilonaceptInterleukin-1 betatarget
DB06372RilonaceptInterleukin-1 alphatarget
DB06372RilonaceptInterleukin-1 receptor antagonist proteintarget
DB09029SecukinumabInterleukin-17Atarget
DB09036SiltuximabInterleukin-6target
DB09036SiltuximabCytochrome P450 3A4enzyme
DB01281AbataceptT-lymphocyte activation antigen CD80target
DB01281AbataceptT-lymphocyte activation antigen CD86target
DB05676ApremilastPhosphodiesterase isozyme 4target
DB05676ApremilastCytochrome P450 3A4enzyme
DB05676ApremilastCytochrome P450 2A6enzyme
DB05676ApremilastCytochrome P450 1A2enzyme